



HIGHTIDE THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE 2019 IN SAN FRANCISCO

Founder CEO & CSO Dr. Liping Liu to provide introduction and overview of HTD1801, the company's lead drug candidate for chronic liver diseases (NASH, PSC)

ROCKVILLE, MD, USA, December 11, 2018 /EINPresswire.com/ -- Dr. Liping Liu, Founder, CEO and CSO will present at Biotech Showcase™ as follows:

Date: Tuesday, January 8, 2019

Time: 3:00 PM (PST)

Room: Franciscan C (Ballroom Level)

Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, CA (United States)

"We are honored that HighTide has been selected to present at Biotech Showcase. 2019 will be an exciting year for our company and we are pleased to have this opportunity to introduce HighTide and its pipeline of innovative therapies for patients suffering from non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and acute pancreatitis, diseases that lack approved therapies," said Liping Liu, Founder, CEO and CSO of HighTide Therapeutics.

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

"We are delighted that HighTide Therapeutics will be presenting at Biotech Showcase this year," said Sara Demy-Colton, CEO of Demy-Colton. "Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great business development opportunity of 2019."

ABOUT BIOTECH SHOWCASE

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical

executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

ABOUT HIGHTIDE THERAPEUTICS

HighTide Therapeutics Inc., founded in 2011, is dedicated to the discovery and development of innovative therapeutics for people suffering from chronic liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied market needs. For additional information, please visit <https://hightidebio.com/>.

Jeffrey Dao

HighTide Therapeutics

[email us here](#)

+1 6505803872

This press release can be viewed online at: <https://www.einpresswire.com/article/470713313>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.